89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...

In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...

Pegozafermin is under clinical development by 89Bio and currently in Phase III for Fibrosis. According to GlobalData, Phase III drugs for Fibrosis does not have sufficient historical data to build an ...

Pegozafermin is under clinical development by 89Bio and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase III drugs for Liver Cirrhosis have a 44% phase transition success ...

We are excited to announce that makers can now visualize and manage existing tables in the ERD table designer, data workspace! Now, instead of starting from scratch, you can use your existing tables ...

The firm's confidence in the biopharmaceutical company's prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG).

Additionally, the ongoing Phase 3 ENLIGHTEN program in NASH, which investigates pegozafermin in both non-cirrhotic and cirrhotic conditions, has garnered significant interest from key opinion ...

The 2024-25 Premier League table promises to be tight from top to bottom as some almighty scraps will take place over the next nine months. [ MORE: Premier League 2024-25 schedule, how to watch live] ...

Football's Writer Program can give you the edge you need to get ahead. Apply Now ...